Anixa Biosciences, Inc.
ANIX · NASDAQ
10/31/2025 | 10/31/2024 | 10/31/2023 | 10/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.96 | -0.41 | 0.35 | 0.00 |
| FCF Yield | -5.35% | -6.57% | -6.34% | -3.82% |
| EV / EBITDA | -11.37 | -8.74 | -8.86 | -11.51 |
| Quality | ||||
| ROIC | -82.67% | -72.34% | -46.76% | -48.82% |
| Gross Margin | 0.00% | 0.00% | 23.33% | 0.00% |
| Cash Conversion Ratio | 0.65 | 0.58 | 0.63 | 0.47 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | – | -25.70% | – |
| Free Cash Flow Growth | 2.21% | -18.13% | 4.36% | -31.50% |
| Safety | ||||
| Net Debt / EBITDA | 0.09 | 0.08 | 0.07 | 0.88 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -133.41 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 2.27 | 0.00 |